Better Diagnosis = Better Patient Outcomes

Simple, rapid diagnostic tools will immensely facilitate allocation of medical resources required to treat TBI and other brain injuries in military combat and civilian emergencies.

We know that better diagnosis will result in better patient outcomes. Accurate and early diagnosis in acute care environments can significantly simplify decisions about patient management including whether to admit, discharge or to administer other time consuming, expensive and often inaccurate diagnostic tests including computed tomography (CT) and magnetic resonance imaging (MRI) scans.

Banyan Biomarkers = Better Diagnosis

Banyan is uniquely qualified to develop better diagnostics that will result in better management and treatment of brain injury patients.

• Powerful Discovery Platform
  

  Novel integration of insights into cell pathobiology and clinical utility closely linked to cutting edge, patented biochemical technologies including high-throughput proteomic capabilities. Rapid biomarker screening and selection using preclinical validation, expediting early human clinical validation. Platform technologies applicable to diagnostics for other organ systems, such as the heart and liver.

• Unmatched Biomarker Pipeline
  Multiple (42+) unique, proprietary biomarkers in the Banyan development pipeline. Biomarkers selected to assist in identification of brain injury specificity, location and severity -- attributes that do not exist today.
  

Better Diagnosis = Better Treatments
Banyan's scientific team has integrated breakthrough thinking and cutting edge technology to focus on the therapeutic opportunities created by biomarker discovery.